ARVINAS, INC. Increase (Decrease) in Accrued Liabilities
ARVINAS, INC. (ARVN) reported Increase (Decrease) in Accrued Liabilities of $7.00 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2022-05-05
- ARVINAS, INC. increase (decrease) in accrued liabilities for the quarter ending 2022-03-31 was $7.00M.
- ARVINAS, INC. increase (decrease) in accrued liabilities for the quarter ending 2021-12-31 was $9.29M, a 48.43% increase year-over-year.
- ARVINAS, INC. increase (decrease) in accrued liabilities for the quarter ending 2021-09-30 was $296.25K, a 93.75% decline year-over-year.
- ARVINAS, INC. increase (decrease) in accrued liabilities for the quarter ending 2021-06-30 was $5.51M, a 788.16% increase year-over-year.
- ARVINAS, INC. increase (decrease) in accrued liabilities for fiscal 2021 was $4.20M, a 61.11% decline from fiscal 2020.
- ARVINAS, INC. increase (decrease) in accrued liabilities for fiscal 2020 was $10.80M, a 200.00% increase from fiscal 2019.
- ARVINAS, INC. increase (decrease) in accrued liabilities for fiscal 2019 was $3.60M, a 494.71% increase from fiscal 2018.
- ARVINAS, INC. increase (decrease) in accrued liabilities for fiscal 2018 was $605.34K, a 68.04% decline from fiscal 2017.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-03-31 | $7.00M 10-Q · filed 2022-05-05 | $16.29M derived: sum of 2 quarters · filed 2022-05-05 | $16.59M derived: sum of 3 quarters · filed 2022-05-05 | $22.10M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-12-31 | $9.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $9.59M derived: sum of 2 quarters · filed 2022-02-28 | $15.10M derived: sum of 3 quarters · filed 2022-02-28 | $4.20M 10-K · filed 2022-02-28 | ||
| 2021-09-30 | $296.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $5.81M derived: sum of 2 quarters · filed 2021-11-03 | -$5.09M 10-Q · filed 2021-11-03 | $1.17M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-06-30 | $5.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$5.39M 10-Q · filed 2021-08-05 | $872.30K derived: sum of 3 quarters · filed 2022-05-05 | $5.61M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-03-31 | -$10.90M 10-Q · filed 2022-05-05 | -$10.86M 10-Q · filed 2021-05-04 | -$4.64M derived: sum of 2 quarters · filed 2022-05-05 | $98.44K derived: sum of 3 quarters · filed 2022-05-05 | $719.18K derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $6.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $11.00M derived: sum of 2 quarters · filed 2022-02-28 | $11.62M derived: sum of 3 quarters · filed 2022-02-28 | $10.80M 10-K · filed 2022-02-28 | $10.81M 10-K · filed 2021-03-01 | |
| 2020-09-30 | $4.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $5.36M derived: sum of 2 quarters · filed 2021-11-03 | $4.54M 10-Q · filed 2021-11-03 | $5.92M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $620.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$198.44K 10-Q · filed 2021-08-05 | $1.18M derived: sum of 3 quarters · filed 2022-02-28 | $3.40M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$819.18K 10-Q · filed 2021-05-04 | $555.13K derived: sum of 2 quarters · filed 2022-02-28 | $2.78M derived: sum of 3 quarters · filed 2022-02-28 | $3.83M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.60M derived: sum of 2 quarters · filed 2022-02-28 | $4.65M derived: sum of 3 quarters · filed 2022-02-28 | $3.60M 10-K · filed 2022-02-28 | $3.60M 10-K · filed 2020-03-16 | |
| 2019-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.28M derived: sum of 2 quarters · filed 2020-11-05 | $2.23M 10-Q · filed 2020-11-05 | $2.51M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$2.30K 10-Q · filed 2020-08-04 | $283.38K derived: sum of 3 quarters · filed 2021-03-01 | $2.16M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | -$1.05M 10-Q · filed 2020-04-28 | -$768.04K derived: sum of 2 quarters · filed 2021-03-01 | $1.11M derived: sum of 3 quarters · filed 2021-03-01 | $1.48M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $285.68K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.17M derived: sum of 2 quarters · filed 2021-03-01 | $2.53M derived: sum of 3 quarters · filed 2021-03-01 | $605.34K 10-K · filed 2021-03-01 | $455.34K 10-K · filed 2019-03-26 | |
| 2018-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $2.25M derived: sum of 2 quarters · filed 2019-11-04 | $319.66K 10-Q · filed 2019-11-04 | $1.92M derived: sum of 4 quarters · filed 2019-11-04 | ||
| 2018-06-30 | $367.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$1.56M 10-Q · filed 2019-08-05 | $43.41K derived: sum of 3 quarters · filed 2019-08-05 | |||
| 2018-03-31 | -$1.93M 10-Q · filed 2019-05-09 | -$323.90K derived: sum of 2 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $1.89M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $289.80K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |